Companies /Healthcare

Intellia Therapeutics Inc

NASDAQ: NTLA Biotechnology
$12.74
▲ $0.06 (+0.47%) today
Markets closed · 4:18pm ET

Q2 2026 Earnings

Reported Aug 6, 2026, 7:45am ET · SEC source
$-0.80
Beat −1.95%
EPS · est. $-0.90 GAAP
$7.7M
Miss −40.99%
Revenue · est. $13.0M
7 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
0+4%+8%+12%Aug 6Aug 7report 7:45am ETearnings+0.2%+12.5%
0+4%+8%+12%Aug 6Aug 7earnings+0.2%+12.5%
NTLA +12.5%S&P 500 +0.2%
0+4%+8%+12%Aug 6Aug 7report 7:45am ETearnings+1.0%+12.5%
0+4%+8%+12%Aug 6Aug 7earnings+1.0%+12.5%
NTLA +12.5%NASDAQ +1.0%
0+5%+10%+15%Aug 5Aug 14report 7:45am ETearnings+1.0%+12.0%
0+5%+10%+15%Aug 5Aug 14earnings+1.0%+12.0%
NTLA +12.0%S&P 500 +1.0%
0+5%+10%+15%Aug 5Aug 14report 7:45am ETearnings+2.8%+12.0%
0+5%+10%+15%Aug 5Aug 14earnings+2.8%+12.0%
NTLA +12.0%NASDAQ +2.8%
+2.46%
Day of report
+6.23%
Next session
+5.25%
One week

Did NTLA Beat Earnings? Q2 2026 Results

Intellia Therapeutics delivered a mixed second quarter for 2026, missing on both the top and bottom lines even as a landmark clinical readout underscored the promise of its gene editing platform. The company posted a GAAP net loss of $0.80 per share, falling short of the $0.78 consensus by 1.95%, snapping a streak of six consecutive quarterly EPS beats. Collaboration revenue tumbled 46.2% year over year to $7.66 million, coming in well below the $12.98 million analysts had expected, as reduced contributions from Regeneron on the nex-z program weighed heavily on the top line. The headline story, however, was the Phase 3 HAELO trial for lonvoguran ziclumeran in hereditary angioedema, which demonstrated an 87% reduction in attacks versus placebo and was published in the New England Journal of Medicine. G&A expenses climbed to $37.82 million from $27.21 million a year ago, reflecting aggressive commercial buildout ahead of a planned U.S. launch in the first half of 2027, contingent on BLA acceptance expected later this year. Intellia ended the quarter with $628.35 million in cash, providing runway into at least 2028.

Key Takeaways
  • Positive Phase 3 HAELO data for lonvo-z driving regulatory and commercial momentum
  • R&D expense reduction driven by lower external costs on lead development programs and reduced stock-based compensation
  • G&A expense increase driven by commercial infrastructure buildout for anticipated lonvo-z launch
  • Collaboration revenue decline primarily due to reduced revenue from Regeneron

“The second quarter was a momentous period for Intellia highlighted by the positive Phase 3 HAELO clinical trial results we reported for lonvo-z in hereditary angioedema. These data serve as strong validation for in vivo gene editing and lonvo-z's potential to transform the treatment paradigm for patients who are burdened by this disease.”

Intellia Therapeutics CEO, on the earnings call

Forward Guidance & Outlook

Intellia expects FDA acceptance of its BLA submission for lonvo-z in the second half of 2026, with a planned U.S. commercial launch in the first half of 2027. The company expects to complete MAGNITUDE-2 enrollment for nex-z in ATTRv-PN in the second half of 2026. Cash, cash equivalents and marketable securities of approximately $628 million are expected to fund operations at least into 2028 and well beyond lonvo-z's anticipated U.S. commercial launch, excluding potential commercial revenues from lonvo-z.

NTLA YoY Financials

Q2 2026 vs Q2 2025 · SEC filings Q2 2025 Q2 2026
$-120,000,000$-80,000,000$-40,000,000$0$14.2M$7.7MRevenue$-115,663,145$-112,760,000Operating Income$-112,613,792$-106,634,000Net Income
$-120,000,000$-80,000,000$-40,000,000$0RevenueOperating IncomeNet Income

NTLA Revenue by Segment

Collaboration Revenue$7.7M
Collaboration Revenue (Regeneron)

Figures from SEC filings and company reports. Not investment advice.